Injection treatment for B-cell lymphoma that has returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of non-Hodgkin B-cell lymphoma (or CLL/SLL) that has returned or not responded after at least two previous treatments.
- Your cancer has not spread to the brain or spinal cord.
- You have not had a Richter's transformation (your CLL changed into a more aggressive lymphoma).
- Your organs (like liver, kidneys, heart) are working well enough as checked by blood tests and heart scans.
- You are able to care for yourself (ECOG score 0-2) and are expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
This trial tests a new immune cell treatment for adults with a type of blood cancer (B-cell lymphoma) that has come back or not improved after standard treatments. The therapy uses specially engineered immune cells to target and destroy cancer cells.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
Hear when a new Transformed Follicular Lymphoma (TFL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.